Biocon Ltd, a biopharmaceutical company headquartered in Bengaluru, is set to raise $30 million for its biosimilar unit from a private equity fund managed by Tata Capital Ltd. In a separate development, Canada-based Brookfield Asset Management has initiated talks with Bengaluru-based developer RMZ Corp to acquire a part of its office projects, per a report by VC Circle.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
